<DOC>
	<DOC>NCT01879618</DOC>
	<brief_summary>The study will determine if the Fragmin dose can be adjusted to suit the clinical needs of patients during dialysis.</brief_summary>
	<brief_title>Use Of Fragmin In Hemodialysis</brief_title>
	<detailed_description />
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Kidney Failure, Chronic</mesh_term>
	<mesh_term>Dalteparin</mesh_term>
	<mesh_term>Heparin, Low-Molecular-Weight</mesh_term>
	<criteria>chronic renal failure on hemodialysis significant comorbidities that would prevent a patient from completing the trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Fragmin</keyword>
	<keyword>dalteparin</keyword>
	<keyword>hemodialysis</keyword>
	<keyword>anticoagulation</keyword>
	<keyword>Renal Failure</keyword>
</DOC>